Regeneron Receives Fast Track Designation from U.S. FDA for REGN 2477

Speeding up the process

Today, August 3, 2017, Regeneron Pharmaceuticals reported earnings including an announcement that Regeneron has received Fast Track Designation from the U.S. Food & Drug Administration (FDA) for REGN 2477. Fast Track Designation allows for companies to have more frequent engagement with the FDA and allows a company to be eligible for accelerated approval/priority review (a 6-month review timeline). Only drugs being developed for serious, unmet medical conditions can receive Fast Track Designation. Congratulations to Regeneron for achieving this important milestone!

Regeneron_Logo.png

Make a Difference

Donate Connect Fundraise
Already a Member? Sign In

Sign Up for FOP Connection, Our Monthly eNewsletter